Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

Leishmaniasis

University of California, San Francisco – Leishmaniasis, Cutaneous University of California, San Francisco – Leishmaniasis, Mucocutaneous Universidad Peruana Cayetano Heredia – Cutaneous Leishmaniasis U.S. Army Medical Research and Materiel Command – Leishmaniasis, Cutaneous University of California, San Francisco – Leishmaniasis U.S. Army Medical Research and Materiel Command – Leishmaniasis

Clinical Prognostic Score to Predict Relapse in VL Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre Defining Skin Immunity of a Bite of Key Insect Vectors in Humans Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank Single Oral Dose Escalation Study of DNDI-0690 in Healthy Male Subjects Clinical Investigation of Infections Due to Leishmanial Parasites Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Diagnosis and Treatment of Leishmanial Infections Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis. Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite WR 279,396 Open Label Treatment Protocol in Tunisia Pharmacokinetics of Miltefosine in Children and Adults Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Miltefosine for Mucosal Leishmaniasis Asymptomatic Leishmania Infection in HIV Patients Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Miltefosine for Brazilian Visceral Leishmaniasis Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa LAMP Assay for the Diagnosis of Visceral Leishmaniasis Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis A Community Trial for Visceral Leishmaniasis (VL) Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry Mediterranean Visceral Leishmaniasis With Leishmania Infantum Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia Surveillance for Leishmaniasis Skin Lesions in Mali Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Expression of Mif Alleles in Individuals With Leishmaniasis Miltefosine and GM-CSF in Cutaneous Leishmaniasis Immunogenetics of Visceral Leishmaniasis Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) WR 279,396 for the Treatment of Cutaneous Leishmaniasis A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Amphotericin B Treatment in Visceral Leishmaniasis The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil Miltefosine to Treat Mucocutaneous Leishmaniasis Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Improved Case Detection and Vector Control for Visceral Leishmaniasis Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar SCH708980 With and Without AmBisome for Visceral Leishmaniasis Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Combination Chemotherapy for the Treatment of Indian Kala-Azar Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Sodium Stibogluconate Treatment of Leishmaniasis A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396